Form DEFA14A Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare ConferenceBusiness Wire
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $17.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
MCRB
Earnings
- 11/2/22 - Miss
MCRB
Sec Filings
- 3/7/23 - Form S-8
- 3/7/23 - Form 10-K
- 3/7/23 - Form 8-K
- MCRB's page on the SEC website